[
    [
        {
            "time": "",
            "original_text": "【国盛医药张金洋团队】沃森生物：创新基因驱动发展，疫苗第二波大浪潮重磅产品处于审批尾声",
            "features": {
                "keywords": [
                    "沃森生物",
                    "创新基因",
                    "疫苗",
                    "第二波大浪潮",
                    "审批尾声"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【国盛医药张金洋团队】沃森生物：创新基因驱动发展，疫苗第二波大浪潮重磅产品处于审批尾声",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "沃森生物(300142.SZ)拟通过沃嘉生物持有JHBP (CY)股权 推进嘉和生物境外上市的股权重组",
            "features": {
                "keywords": [
                    "沃森生物",
                    "股权重组",
                    "嘉和生物",
                    "境外上市"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "沃森生物(300142.SZ)拟通过沃嘉生物持有JHBP (CY)股权 推进嘉和生物境外上市的股权重组",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "沃森生物：疫苗第二波大浪潮重磅产品处于审批尾声 买入评级",
            "features": {
                "keywords": [
                    "沃森生物",
                    "疫苗",
                    "第二波大浪潮",
                    "审批尾声",
                    "买入评级"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沃森生物：疫苗第二波大浪潮重磅产品处于审批尾声 买入评级",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]